vs
Side-by-side financial comparison of Dingdong (Cayman) Ltd (DDL) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $115.3M, roughly 1.5× Dingdong (Cayman) Ltd).
Dingdong (Cayman) Ltd operates a leading on-demand grocery e-commerce platform primarily serving the Chinese market. It provides fresh produce, daily necessities, ready-to-eat meals, and household staples to urban consumers, leveraging optimized supply chains and localized logistics networks to offer fast, reliable 30-minute delivery services, prioritizing product freshness and user convenience.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
DDL vs ESPR — Head-to-Head
Income Statement — Q3 FY2022 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.3M | $168.4M |
| Net Profit | $6.7M | — |
| Gross Margin | — | — |
| Operating Margin | 5.3% | 50.6% |
| Net Margin | 5.8% | — |
| Revenue YoY | — | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.02 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $168.4M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | — | $82.4M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | — | $51.6M | ||
| Q2 24 | — | $73.8M | ||
| Q1 24 | — | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | — | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-29.5M | ||
| Q2 24 | — | $-61.9M | ||
| Q1 24 | — | $61.0M |
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | — | -31.0% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | — | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | — | -83.9% | ||
| Q1 24 | — | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $113.7M | $167.9M |
| Total DebtLower is stronger | $135.8K | — |
| Stockholders' EquityBook value | $4.5M | $-302.0M |
| Total Assets | $178.3M | $465.9M |
| Debt / EquityLower = less leverage | 0.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | — | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | — | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | — | $-370.2M | ||
| Q2 24 | — | $-344.2M | ||
| Q1 24 | — | $-294.3M |
| Q4 25 | — | $465.9M | ||
| Q3 25 | — | $364.0M | ||
| Q2 25 | — | $347.1M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | — | $314.1M | ||
| Q2 24 | — | $352.3M | ||
| Q1 24 | — | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.2M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-31.4M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-35.0M | ||
| Q3 24 | — | $-35.3M | ||
| Q2 24 | — | $-7.2M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DDL
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
